Krystal Biotech (KRYS) expects to raise $30 million in an IPO on Wednesday, September 20th, IPO Scoop reports. The company plans to issue 3,000,000 shares at $9.00-$11.00 per share.

Krystal Biotech has a market cap of $86.8 million.

Ladenburg Thalmann served as the underwriter for the IPO.

Krystal Biotech provided the following description of their company for its IPO: “We are a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases. We have developed a proprietary gene therapy platform, which we refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which we believe there are no known effective treatments. We are initially using the STAR-D platform to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene, and plan to leverage our platform to expand our pipeline to include other dermatological indications in the future. “.

Krystal Biotech was founded in 2015 and has 7 employees. The company is located at 2100 Wharton Street, Suite 701, Pittsburgh, PA 15203, US and can be reached via phone at (412) 586-5830 or on the web at http://www.krystalbio.com.

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.